Page 2,886«..1020..2,8852,8862,8872,888..2,9002,910..»

Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage

Posted: January 31, 2012 at 2:09 am

Public release date: 30-Jan-2012
[ | E-mail | Share ]

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center

STANFORD, Calif. ? Mouse skin cells can be converted directly into cells that become the three main parts of the nervous system, according to researchers at the Stanford University School of Medicine. The finding is an extension of a previous study by the same group showing that mouse and human skin cells can be directly converted into functional neurons.

The multiple successes of the direct conversion method could refute the idea that pluripotency (a term that describes the ability of stem cells to become nearly any cell in the body) is necessary for a cell to transform from one cell type to another. Together, the results raise the possibility that embryonic stem cell research and another technique called "induced pluripotency" could be supplanted by a more direct way of generating specific types of cells for therapy or research.

This new study, which will be published online Jan. 30 in the Proceedings of the National Academy of Sciences, is a substantial advance over the previous paper in that it transforms the skin cells into neural precursor cells, as opposed to neurons. While neural precursor cells can differentiate into neurons, they can also become the two other main cell types in the nervous system: astrocytes and oligodendrocytes. In addition to their greater versatility, the newly derived neural precursor cells offer another advantage over neurons because they can be cultivated to large numbers in the laboratory ? a feature critical for their long-term usefulness in transplantation or drug screening.

In the study, the switch from skin to neural precursor cells occurred with high efficiency over a period of about three weeks after the addition of just three transcription factors. (In the previous study, a different combination of three transcription factors was used to generate mature neurons.) The finding implies that it may one day be possible to generate a variety of neural-system cells for transplantation that would perfectly match a human patient.

"We are thrilled about the prospects for potential medical use of these cells," said Marius Wernig, MD, assistant professor of pathology and a member of Stanford's Institute for Stem Cell Biology and Regenerative Medicine. "We've shown the cells can integrate into a mouse brain and produce a missing protein important for the conduction of electrical signal by the neurons. This is important because the mouse model we used mimics that of a human genetic brain disease. However, more work needs to be done to generate similar cells from human skin cells and assess their safety and efficacy."

Wernig is the senior author of the research. Graduate student Ernesto Lujan is the first author.

While much research has been devoted to harnessing the pluripotency of embryonic stem cells, taking those cells from an embryo and then implanting them in a patient could prove difficult because they would not match genetically. An alternative technique involves a concept called induced pluripotency, first described in 2006. In this approach, transcription factors are added to specialized cells like those found in skin to first drive them back along the developmental timeline to an undifferentiated stem-cell-like state. These "iPS cells" are then grown under a variety of conditions to induce them to re-specialize into many different cell types.

Scientists had thought that it was necessary for a cell to first enter an induced pluripotent state or for researchers to start with an embryonic stem cell, which is pluripotent by nature, before it could go on to become a new cell type. However, research from Wernig's laboratory in early 2010 showed that it was possible to directly convert one "adult" cell type to another with the application of specialized transcription factors, a process known as transdifferentiation.

Wernig and his colleagues first converted skin cells from an adult mouse to functional neurons (which they termed induced neuronal, or iN, cells), and then replicated the feat with human cells. In 2011 they showed that they could also directly convert liver cells into iN cells.

"Dr. Wernig's demonstration that fibroblasts can be converted into functional nerve cells opens the door to consider new ways to regenerate damaged neurons using cells surrounding the area of injury," said pediatric cardiologist Deepak Srivastava, MD, who was not involved in these studies. "It also suggests that we may be able to transdifferentiate cells into other cell types." Srivastava is the director of cardiovascular research at the Gladstone Institutes at the University of California-San Francisco. In 2010, Srivastava transdifferentiated mouse heart fibroblasts into beating heart muscle cells.

"Direct conversion has a number of advantages," said Lujan. "It occurs with relatively high efficiency and it generates a fairly homogenous population of cells. In contrast, cells derived from iPS cells must be carefully screened to eliminate any remaining pluripotent cells or cells that can differentiate into different lineages." Pluripotent cells can cause cancers when transplanted into animals or humans.

The lab's previous success converting skin cells into neurons spurred Wernig and Lujan to see if they could also generate the more-versatile neural precursor cells, or NPCs. To do so, they infected embryonic mouse skin cells ? a commonly used laboratory cell line ? with a virus encoding 11 transcription factors known to be expressed at high levels in NPCs. A little more than three weeks later, they saw that about 10 percent of the cells had begun to look and act like NPCs.

Repeated experiments allowed them to winnow the original panel of 11 transcription factors to just three: Brn2, Sox2 and FoxG1. (In contrast, the conversion of skin cells directly to functional neurons requires the transcription factors Brn2, Ascl1 and Myt1l.) Skin cells expressing these three transcription factors became neural precursor cells that were able to differentiate into not just neurons and astrocytes, but also oligodendrocytes, which make the myelin that insulates nerve fibers and allows them to transmit signals. The scientists dubbed the newly converted population "induced neural precursor cells," or iNPCs.

In addition to confirming that the astrocytes, neurons and oligodendrocytes were expressing the appropriate genes and that they resembled their naturally derived peers in both shape and function when grown in the laboratory, the researchers wanted to know how the iNPCs would react when transplanted into an animal. They injected them into the brains of newborn laboratory mice bred to lack the ability to myelinate neurons. After 10 weeks, Lujan found that the cells had differentiated into oligodendroytes and had begun to coat the animals' neurons with myelin.

"Not only do these cells appear functional in the laboratory, they also seem to be able to integrate appropriately in an in vivo animal model," said Lujan.

The scientists are now working to replicate the work with skin cells from adult mice and humans, but Lujan emphasized that much more research is needed before any human transplantation experiments could be conducted. In the meantime, however, the ability to quickly and efficiently generate neural precursor cells that can be grown in the laboratory to mass quantities and maintained over time will be valuable in disease and drug-targeting studies.

"In addition to direct therapeutic application, these cells may be very useful to study human diseases in a laboratory dish or even following transplantation into a developing rodent brain," said Wernig.

###

In addition to Wernig and Lujan, other Stanford researchers involved in the study include postdoctoral scholars Soham Chanda, PhD, and Henrik Ahlenius, PhD; and professor of molecular and cellular physiology Thomas Sudhof, MD.

The research was supported by the California Institute for Regenerative Medicine, the New York Stem Cell Foundation, the Ellison Medical Foundation, the Stinehart-Reed Foundation and the National Institutes of Health.

The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html.

PRINT MEDIA CONTACT: Krista Conger at (650) 725-5371 (kristac@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)

[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Visit link:
Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage

StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

Posted: January 30, 2012 at 4:29 pm

NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM
-
News) today announced the publication of preclinical data
demonstrating that its proprietary HuCNS-SC(R) cells (purified
human neural stem
cells) protect host photoreceptors and preserve vision
in an animal model of retinal disease. The preclinical
results are highly relevant to human disorders of vision loss,
the most notable of which is dry age-related macular degeneration
(AMD). The study is available online at
http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract
and will be featured as the cover article in the February issue
of the international peer-reviewed European Journal of
Neuroscience.

This research was conducted in collaboration with a team of
researchers led by Raymond Lund, Ph.D., Professor Emeritus of
Ophthalmology, and Trevor McGill, Ph.D., Research Assistant
Professor at the Casey Eye Institute, Oregon Health and Science
University.

The results of the study show that photoreceptors, the key
cells of the eye involved in vision, were protected from
degeneration following transplantation of HuCNS-SC cells into
the Royal College of Surgeons (RCS) rat. The RCS rat is a
well-established model of retinal disease which has been used
extensively to evaluate potential cell therapies. Moreover, the
number of cone photoreceptors, which are responsible for
central vision, remained constant over an extended period,
consistent with the sustained visual acuity and light
sensitivity observed in the study. In humans, degeneration of
the cone photoreceptors account for the unique pattern of
visual loss in dry AMD.

"These results are the most robust shown to date in this animal
model," said Dr. Lund, one of the study's lead investigators.
"One of the more striking findings is that the effect on vision
was long-lasting and correlated with the survival of HuCNS-SC
cells more than seven months after transplantation, which is
substantially longer than other cell types transplanted into
this same model. Also important, particularly for potential
clinical application, was that the cells spread from the site
of initial application to cover more of the retina over time.
These data suggest that HuCNS-SC cells appear to be a
well-suited candidate for cell therapy in retinal degenerative
conditions."

Alexandra Capela, Ph.D., another of the study's investigators
and a senior scientist at StemCells, commented, "This study
showed that the HuCNS-SC cells persisted and migrated
throughout the retina, with no evidence of abnormal cell
formation, which supports our hypothesis of a single transplant
therapeutic. With this research, then, we have shown that
vision can be positively impacted with a simple approach that
does not require replacing photoreceptors or the RPE cells. We
look forward to investigating this promising approach in the
clinic later this year."

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and
commercialization of cell-based therapeutics and tools for use
in stem cell-based research and drug discovery. The Company's lead
therapeutic product candidate, HuCNS-SC(R) cells (purified
human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system
disorders. Clinical trials are currently underway in spinal
cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children. In addition, the Company
plans to initiate a clinical trial of HuCNS-SC cells in the dry
form of age-related macular degeneration in 2012, and is also
pursuing preclinical studies of its HuCNS-SC cells in
Alzheimer's disease. StemCells also markets stem cell research
products, including media and reagents, under the SC Proven(R)
brand, and is developing stem cell-based assay platforms for
use in pharmaceutical research, drug discovery and drug
development. Further information about StemCells is available
at
http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this
press release constitutes forward-looking statements within the
meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to
the safe harbors created therein. These statements include, but
are not limited to, statements regarding the prospect of the
Company's HuCNS-SC cells to preserve vision in animal models of
retinal disease; the prospect of successful results from this
research collaboration and advancing to clinical testing in
age-related macular degeneration or other retinal disease; the
potential of the Company's HuCNS-SC cells to treat a broad
range of central nervous system disorders; the prospect and
timing associated with initiating a clinical trial in a retinal
disorder; and the future business operations of the Company,
including its ability to conduct clinical trials as well as its
other research and product development efforts. These
forward-looking statements speak only as of the date of this
news release. The Company does not undertake to update any of
these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks
and uncertainties to which the Company is subject, including
the fact that additional trials will be required to demonstrate
the safety and efficacy of the Company's HuCNS-SC cells for the
treatment of any disease or disorder; uncertainty as to whether
the results of the Company's preclinical studies in retinal
disease will be replicated in humans; uncertainty as to whether
the FDA or other applicable regulatory agencies will permit the
Company to continue clinical testing in spinal cord injury, PMD
or in future clinical trials of proposed therapies for other
diseases or conditions given the novel and unproven nature of
the Company's technologies; uncertainties regarding the
Company's ability to recruit the patients required to conduct
its clinical trials or to obtain meaningful results;
uncertainties regarding the Company's ability to obtain the
increased capital resources needed to continue its current and
planned research and development operations; uncertainty as to
whether HuCNS-SC and any products that may be generated in the
future in the Company's cell-based programs will prove safe and
clinically effective and not cause tumors or other adverse side
effects; uncertainties regarding the Company's ability to
commercialize a therapeutic product and its ability to
successfully compete with other products on the market; and
other factors that are described under the heading "Risk
Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 2010, and in its subsequent reports on
Forms 10-Q and 8-K.

Read more:
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

Posted in Stem Cell Videos | Comments Off on StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

Gingrich Vows to Ban Embryonic Stem Cell Research

Posted: January 30, 2012 at 4:28 pm

(Photo: REUTERS/Shannon Stapleton)

U.S. Republican presidential candidate and former Speaker
of the House Newt Gingrich (R) speaks to the media after
attending a church service at the Exciting Idlewild
Baptist Church in Lutz, Florida January 29, 2012.

"I believe life begins at conception," the Republican
presidential hopeful stressed Sunday at a news conference
outside a Baptist church in Lutz, Fla.

"The question I was raising was what happens to embryos in
fertility clinics," Gingrich added, referring to the remarks he
made a day earlier at another Baptist church in Winter Park,
that embryonic stem-cell research amounts to "the use of
science to
desensitize society over the killing of babies."

Gingrich's proposal was seen as an attempt to woo evangelical
voters and gain an edge over former Mass. Gov. Mitt Romney, his biggest opponent in
Florida.

Gingrich went on to say he was in favor of a commission to
"look seriously" at the ethics of how fertility clinics are
managed. "If you have in vitro fertilization, you are creating
life; therefore, we should look seriously at what the rules
should be for clinics that are doing that, because they are
creating life," The Associated Press quoted him as saying
outside Exciting Idlewild Baptist Church.

Gingrich, who vocally supported federally funded research about
a decade ago, said he was also against the use of leftover
embryos for stem cell research.

Like us on Facebook

In vitro fertilization or IVF refers to formation of an embryo
outside a woman's body for implant inside the womb. Human
embryos can also be used in treatment or cure of illnesses and
injuries but they have life, conservatives say.

In 2009, President Barack Obama lifted restrictions on federal
funding for stem cell research, which were put in place by his
predecessor, George W. Bush in 2001.

Romney, who is not against the use of stem cell research on
excess embryos in fertility clinics, is leading in polls in
Florida. Reuters/Ipsos online poll results released Sunday
showed Romney having the support of 42 percent of likely voters
while Gingrich's support stood at 30 percent.

"It's clear that Romney's run a much more focused and effective
campaign in Florida than Newt," Republican strategist Matt
Mackowiak said Sunday, according to Reuters. "Newt's playing
defense every single day in every way and doesn't seem to be
able to make Romney play defense."

Excerpt from:
Gingrich Vows to Ban Embryonic Stem Cell Research

Posted in Stem Cell Research | Comments Off on Gingrich Vows to Ban Embryonic Stem Cell Research

Stem cell treatment for animals – Video

Posted: January 30, 2012 at 11:48 am

26-01-2012 02:37 Animacel ltd. is offering your animal stem cell treatment with newly developed stem cell therapy. At the moment, excellent results are with treatments of different joint problems (arthritis and injury/damage of cartilage, hip dysplasia), tendon problems and supporting/adjuvant stem cell therapy for faster healing of broken bones. We are also developing treatment for heart insufficiency, eye dissease, diabetes, etc. See our webpage http://www.animacel.com

More here:
Stem cell treatment for animals - Video

Posted in Stem Cell Therapy | Comments Off on Stem cell treatment for animals – Video

Lecture by stem cell researcher tomorrow

Posted: January 29, 2012 at 8:06 pm

Celebrated adult stem cell researcher Shinya Yamanaka will
deliver a lecture, ‘New era of medicine with iPS cells', here
on Monday as part of a three-city lecture series. Prof.
Yamanaka's scientific breakthrough was the creation of
embryonic-like stem cells from adult skin cells.

The lecture by this Japanese physician is the third edition of
The Cell Press-TNQ India Distinguished Lectureship Series. He
will also deliver it in Chennai on February 1 and New Delhi on
February 3. The lecture series is co-sponsored by Cell Press
and TNQ Books and Journals.

Quantum leap

The stated goal of Prof. Yamanaka's laboratory has been to
generate pluripotent stem cells from human somatic cells. The
ability to re-programme adult cells back into an earlier,
undifferentiated state has helped to reshape the ethical debate
over stem cell research by providing an approach to obtain
pluripotent stem cells that need not be harvested from an
embryo.

Prof. Yamanaka, who was awarded the Albert Lasker Prize in 2009
and the Wolf Prize in 2011, is the director of the Centre for
iPS Cell Research and Application and professor at the
Institute for Frontier Medical Sciences at Kyoto University. He
is also a senior investigator at the UCSF-affiliated J. David
Gladstone Institutes and a professor of Anatomy at the
University of California in San Francisco.

Previous lectures

The inaugural speaker of the lecture series was American
biologist David Baltimore, who won the 1975 Nobel. The second
speaker was Australia-born American biological researcher
Elizabeth Blackburn, awarded the 2009 Nobel.

The lecture in Bangalore will commence at 4.30 p.m. at J.N.
Tata Auditorium, National Science Seminar Complex, Indian
Institute of Science, C.V. Raman Road.

The rest is here:
Lecture by stem cell researcher tomorrow

Posted in Cell Medicine | Comments Off on Lecture by stem cell researcher tomorrow

Colon Cancer Screening Needed Less Than Every 5 Years

Posted: January 29, 2012 at 4:55 pm

Colon Cancer Screening Needed Less Than Every 5 Years - Colon cancer is easily treated if found early enough, but it appears current recommendations for scope screening every 5 years is unnecessarily frequent.

Sigmoidoscopy screening for colon cancer is recommended every five years for people over 50, however a new study found that screening that often may be unnecessary.

Sigmoidoscopy screening allows a doctor to identify polyps, or small growths, in the colon that could turn into cancer. Other colon cancer screening methods include fecal occult blood testing, which identifies blood in the stool, and colonoscopy, which examines the entire colon (sigmoidoscopy only examines the lower part).

While the American Cancer Society recommends that adults over 50 receive sigmoidoscopy screening every five years and a fecal occult blood test annually, some say this may be overly aggressive.

According to experts, it could take up to 15 years for polyps to develop into cancer and it may be that a one-time sigmoidoscopy screening is enough for those at average-risk. Read more...

AyurGold for Healthy Blood

Source:
http://feeds.feedburner.com/integratedmedicine

Posted in Integrative Medicine | Comments Off on Colon Cancer Screening Needed Less Than Every 5 Years

Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center

Posted: January 29, 2012 at 4:55 pm

Via Scoop.itinPharmatics

Oracle Exadata gets into Personlized Medicine & Bioinformatics space dressed as Oracle® Health Sciences Omics Data Bank.    Oracle Health Sciences today announced availability of Oracle® Health Sciences Omics Data Bank, a molecular data model, which is part of Oracle Health Sciences Translational Research Center.   The new data model provides integration and analysis of cross-platform omics data to support translational research. Oracle Health Sciences Translational Research Center runs on Oracle Exadata Database Machine, delivering the extreme performance required for querying vast data sets.
Via http://www.oracle.com

Source:
http://microarray.wordpress.com/feed/

Posted in Genetic medicine | Comments Off on Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center

Magazine Survey on CIRM Shows Mixed Results

Posted: January 29, 2012 at 4:55 pm


The magazine GEN this week produced two relatively lengthy articles dealing with the current state of affairs and the future of the $3 billion California stem cell agency.

Much of the material is familiar to readers of the California Stem Cell Report, but GEN, which says it reaches "221,035 biotech and life science professionals, also produced an online survey that asked its readers: "How helpful has CIRM been in advancing stem cell science?"

At the time of this writing, the results showed that 40.9 of respondents said CIRM was "very helpful."  An identical percentage said "not very" or were undecided. The survey showed 18.2 percent as ranking the agency "somewhat" helpful. The number of respondents was not disclosed.

The two articles (see here and here)by Alex Philippidis also discussed the possibility of a bond issue in a "few years," before CIRM runs out of cash in 2017. Philippidis wrote,

"By then CIRM hopes to have won what ICOC (the CIRM governing board) chairman Jonathan Thomas, Ph.D., has called the 'communications war' the agency is fighting with California newspapers and the CIRM-focused blog California Stem Cell Report. Both have criticized the agency over a host of governance and pay issues."

For the record, the California Stem Cell Report has not criticized the agency in connection with the level of its executive pay. We have pointed out that many California voters have a highly negative and visceral reaction to high public salaries, which is a matter that CIRM must deal with in connection with retention of public confidence. We have also noted that the salaries represent a tiny, tiny fraction of CIRM spending.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Magazine Survey on CIRM Shows Mixed Results

IOM Panel Ends California Visit With No Mainstream Media Coverage

Posted: January 29, 2012 at 4:55 pm


The blue-ribbon Institute of Medicine panel examining the performance of the $3 billion California stem cell agency has quietly concluded its first public hearing in California without so much as a smidgen of daily coverage in the mainstream media.

Instead, the big state news in California yesterday was a lawsuit filed by lawmakers against the state's top fiscal officer to prevent him from cutting their pay again when they fail to pass a balanced budget.

It would have been extremely unlikely, however, to have seen any daily coverage of the IOM session. The mainstream media generally ignores the affairs of the California stem cell agency.

Other than what has appeared on the California Stem Cell Report, the most comprehensive look at the $700,000, IOM examination of CIRM was provided on Tuesday by Marcy Darnovsky of the Center for Genetics and Society, which has followed CIRM, and the ballot measure that created it, since 2004.

Darnovsky brought her readers on the Biopolitical Times up to speed on CIRM matters. She noted that CIRM will need more cash in a few years when its bond funding runs out. She concluded,

"But ballot measure or no ballot measure, CIRM will continue to disperse the public money it controls - another billion and a half dollars. This is a public agency spending increasingly scarce public resources. It is funding a field of research in which we place great hopes for medical and scientific advances. These factors make it all the more crucial that CIRM follow the basics of good governance and public accountability, and eschew the hyperbole and exaggerated promises that have tainted stem cell research for so long."

The California Stem Cell Report emailed a 1,370-word statement to the panel. The study director of the IOM panel said the statement would be placed in the panel's record.

The document provided perspective on the formation of CIRM, the political context in which it operates and discussed some of the potential pitfalls of CIRM's necessary but delicate courting of industry. Suggestions were offered for changes to ease potential conflicts of interest and to open to the public the statements of the economic interests of the grant reviewers who make the de facto decisions on CIRM's funding.

Here is the full statement from the California Stem Cell Report.
CSCR Statement to IOM-CIRM Performance Inquiry

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on IOM Panel Ends California Visit With No Mainstream Media Coverage

The California Stem Cell Agency and the ACT Opportunity

Posted: January 29, 2012 at 4:55 pm


A promising, positive story on stem cell research in California popped up in the news this week, involving improvements in vision as the result of the only hESC clinical trial in the nation.

The story came after Jonathan Thomas, chairman of the $3 billion California stem cell agency, said in the San Francisco Business Times that what he likes least about his job is that "the coverage in the press chooses to focus on items besides the extraordinary work that our scientists are doing."

The good news about the eye research appeared in the New York Times, Los Angeles Times and across the nation. However, it did not involve work at the stem cell agency, probably for reasons that likely have to do in good part with CIRM. The research involves a firm headquartered in Santa Monica, Ca., Advanced Cell Technology, that moved its base to the Golden State in hopes of securing CIRM funding. ACT has applied more than once for CIRM cash but has never received a grant. And it is one of the rare companies that has complained publicly to the CIRM governing board about a conflict of interest on the part of a CIRM reviewer. In ACT's case, its complaints received a public brushoff at a CIRM board meeting in 2008.

ACT's results in its clinical trial are quite tentative. They involve only two persons. One of the UCLA scientists involved said part of the results could have been the result of a placebo effect. Nonetheless, the reports carried the kind of story line that CIRM yearns for. Indeed, Thomas stressed the need for positive news when he told CIRM directors last June that the agency is in a "communications war" that is tied to its ultimate fate. (The agency runs out of cash in 2017.)

The New York Times' Andy Pollock wrote,

"Both patients, who were legally blind, said in interviews that they had gains in eyesight that were meaningful for them. One said she could see colors better and was able to thread a needle and sew on a button for the first time in years. The other said she was able to navigate a shopping mall by herself."

On its research blog, CIRM described the ACT results as a "milestone." CIRM's Amy Adams wrote,

"It’s the first published paper showing that—at least in this small number of patients for the first few months—the cells are safe."

She quoted Hank Greely of Stanford as saying that the news from ACT is "at least, a little exciting – and in a field that saw its first approved clinical trial stopped two months ago, even a little exciting news is very welcome."

Greely's reference, of course, was to Geron's sudden abandonment in November of its hESC trial, only three months after CIRM gave the firm a $25 million loan. It was widely believed that ACT was one of the initial applicants in the round that provided funding for Geron, although CIRM does not release the names of non-funded applicants.

Last week, CIRM directors spent a fair amount of time discussing the agency's future. The talk was of priorities, hard choices and generating results that would resonate with the people of California.

This week's news from a company that was not funded by CIRM will give them more to ponder.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on The California Stem Cell Agency and the ACT Opportunity

Page 2,886«..1020..2,8852,8862,8872,888..2,9002,910..»